Products Under Development and Intellectual Property
These technologies are currently available for financing, licensing or partnering. Please contact John Dobak, M.D. at jdobak@jakkgroup.com.
MEMS Based Heart Sensor
The JAKK group is leading the development of a novel MEM sensor that that can measure the synchrony of the heart contraction and may help improve the response rate of cardiac resynchronization therapy (CRT). CRT is a pacemaker therapy for heart failure that improves heart function through pacing by causing a more coordinated, or synchronous, contraction of the ventricles. It has been one of the most significant advances in heart failure therapy in the last 30 years. Annual CRT device sales are expected to exceed $4.5 BB in the U.S. alone by 2010.
Cosmetic Pharmaceutical Treatment of Regional Fat Accumulations and Cellulite
Injectable pharmaceutical preparations for cosmetic treatments are a rapidly growing area of medicine as evidenced by the 3 million Botox® injections each year. A similar therapy to treat fat accumulations (e.g under the eyes) and cellulite would be similarly well recieved. The JAKK group is working on a novel drug formulation of previously marketed (FDA approved) drugs for inducing fat cell storage breakdown and inhibiting fat cell growth. It is estimated that $3 BB per annum in the U.S. is spent on products and treatments to improve the appearance of regional fat deposits such as cellulite.
Modulation of Pulmonary Receptors
Stimulation of novel lung receptor targets involved in the control breathing and regulation of cardiovascular physiology may be an effective treatment heart failure and hypertension. In addition, it may treat central sleep disturbance that occurs in heart failure that can lead to severe cardiovascular dysfunction. The therapy may also have application in obstructive sleep apnea. The estimated market potential for implantable modulation of lung receptors exceeds $1.5 BB in the U.S.